# Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

> **NCT01623167** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 207 (actual)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Cohort 1: hATG, CsA, EPAG Day 14 to Month 6
- **DRUG:** Cohort 2: hATG, CsA, EPAG Day 14 to Month 3
- **DRUG:** Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6
- **DRUG:** Extension Cohort

## Key facts

- **NCT ID:** NCT01623167
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-07-02
- **Primary completion:** 2018-01-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623167, "Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01623167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*